IHT Wealth Management LLC increased its stake in shares of Allergan PLC. (NYSE:AGN) by 17.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,084 shares of the company’s stock after buying an additional 600 shares during the period. Allergan PLC. accounts for about 0.6% of IHT Wealth Management LLC’s holdings, making the stock its 27th largest position. IHT Wealth Management LLC’s holdings in Allergan PLC. were worth $971,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Veritas Asset Management LLP bought a new position in shares of Allergan PLC. during the first quarter valued at $761,339,000. Iridian Asset Management LLC CT increased its position in shares of Allergan PLC. by 141.3% in the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after buying an additional 751,848 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Allergan PLC. during the first quarter valued at $124,255,000. Blue Ridge Capital L.L.C. increased its position in shares of Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares during the last quarter. Finally, First Manhattan Co. increased its position in shares of Allergan PLC. by 193.3% in the first quarter. First Manhattan Co. now owns 497,793 shares of the company’s stock valued at $114,646,000 after buying an additional 328,062 shares during the last quarter. Hedge funds and other institutional investors own 84.77% of the company’s stock.

Allergan PLC. (AGN) traded down 0.15% during midday trading on Monday, hitting $242.28. The company’s stock had a trading volume of 543,605 shares. The company’s 50-day moving average is $245.21 and its 200 day moving average is $237.12. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The company has a market cap of $81.37 billion, a price-to-earnings ratio of 7.55 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. The business had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The company’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the company earned $3.35 earnings per share. On average, analysts predict that Allergan PLC. will post $16.20 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is presently 9.95%.

WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/08/07/iht-wealth-management-llc-has-971000-position-in-allergan-plc-agn.html.

AGN has been the subject of several analyst reports. Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price target for the company in a report on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) downgraded Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target for the company. in a report on Wednesday, May 10th. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Royal Bank Of Canada set a $279.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Wednesday, April 12th. Finally, Citigroup Inc. raised their price target on Allergan PLC. to $261.00 and gave the company a “buy” rating in a report on Monday, April 24th. Seven research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Allergan PLC. presently has a consensus rating of “Buy” and a consensus price target of $274.14.

In other news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.36% of the stock is currently owned by corporate insiders.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.